UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 12b-25
NOTIFICATION OF LATE FILING
SEC File Number: 001-41346
CUSIP Number: 67079U 108
(Check one): |
| X Form 10-K | Form 20-F | Form 11-K | Form 10-Q | Form 10-D |
|
| Form N-CEN | Form N-CSR |
|
|
|
|
|
|
|
|
|
|
|
| For Period Ended: | December 31, 2022 |
|
| Transition Report on Form 10-K |
| |
|
| Transition Report on Form 20-F |
| |
|
| Transition Report on Form 11-K |
| |
|
| Transition Report on Form 10-Q |
| |
|
| For the Transition Period Ended: |
| |
Read Instructions (on back page) Before Preparing Form. Please Print or Type. |
If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates: Not Applicable
PART I — REGISTRANT INFORMATION
NUTEX HEALTH INC. |
Full Name of Registrant |
|
Clinigence Holdings, Inc. |
Former Name if Applicable |
|
6030 S. Rice Ave, Suite C |
Address of Principal Executive Office (Street and Number) |
Houston, TX 77081 |
City, State and Zip Code |
PART II — RULES 12b-25(b) AND (c)
If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)
| (a) | The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense |
| | |
X | (b) | The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and |
| (c) | The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable. |
PART III — NARRATIVE
State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.
Nutex Health Inc. (the “Company”) will not, without unreasonable effort and expense, be able to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2022 (the “Form 10-K”) within the prescribed time period due to delays in completion of the financial statements for the fiscal year ended December 31, 2022.
The Form 10-K cannot be filed within the prescribed time period because the Company require additional time to review and finalize its audited financial statements to ensure adequate disclosure of the financial information required to be included in the Form 10-K , including a revision to the valuation of warrants and options that were part of the merger consideration in the reverse merger (the “Merger”) of Clinigence Holdings Inc. (n/k/a Nutex Health Inc.) and Nutex Health Holdco LLC. The Company has dedicated significant resources to completing the Form 10-K and is working diligently to complete the necessary work to file the Form 10-K as soon as practicable within the 15th calendar day following the prescribed due date.
PART IV — OTHER INFORMATION
(1) | Name and telephone number of person to contact in regard to this notification | ||||
| Jon C. Bates |
| 713 |
| 660-0557 |
| (Name) |
| (Area Code) |
| (Telephone Number) |
|
| ||||
(2) | Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). | ||||
|
| ||||
|
|
|
|
| X Yes No |
|
|
|
|
| |
|
|
|
|
|
|
(3) | Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? | ||||
|
| ||||
|
|
|
|
| X Yes No |
|
|
|
|
|
|
| If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.
As disclosed above, the Company’s accounting staff requires additional time to finalize the audited financial statements for the years ended December 31, 2022, and 2021. As disclosed in the Company’s quarterly report on Form 10-Q for the quarter ended September 30, 2022, the Company recognized a non-cash impairment charge of $408.5 million in the three months ended September 30, 2022 to reduce the carrying amount of goodwill arising in the Merger. As a result of a revision in the valuation of warrants and options included in the merger consideration, the impairment charge is expected to be reduced by $10.3 million. The Company has assessed the materiality of this revision and concluded that no restatement of its previous financial disclosure is required. Disclosure Regarding Forward-Looking Statements This Notification of Late Filing on Form 12b-25 contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “expect,” “will,” “anticipates,” “estimates” and variations of such words and similar future or conditional expressions are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding our expectations regarding the timing of the completion of the Company’s financial statements and the filing of the Form 10-Q, which reflect the Company’s expectations based upon currently available information and data. Because such statements are based on the Company’s current expectations and are not statements of fact, actual results may differ materially from those projected or estimated and you are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the Company's control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. The Company disclaims and does not undertake any obligation to update or revise any forward-looking statement in this report, except as required by applicable law or regulation. | ||||
| | ||||
NUTEX HEALTH INC.
(Name of Registrant as Specified in Charter)
has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
Date | March 2, 2023 |
| By | /s/ Jon C. Bates |
|
|
|
| Name: | Jon C. Bates |
|
|
|
| Title: | Chief Financial Officer |
INSTRUCTION: The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative’s authority to sign on behalf of the registrant shall be filed with the form.
| ATTENTION |
|
Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001). | ||
